{"id":10418,"date":"2023-07-13T16:00:27","date_gmt":"2023-07-13T16:00:27","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=10418"},"modified":"2026-01-22T16:16:46","modified_gmt":"2026-01-22T14:16:46","slug":"13juillet-2023-maat-pharma-bilan-semestriel-du-contrat-de-liquidite-contracte-avec-la-societe-de-bourse-kepler-cheuvreux","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/13juillet-2023-maat-pharma-bilan-semestriel-du-contrat-de-liquidite-contracte-avec-la-societe-de-bourse-kepler-cheuvreux\/","title":{"rendered":"13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux"},"content":{"rendered":"<h3 style=\"text-align: center;\"><span style=\"color: #283583;\">MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux\u00a0<\/span><\/h3>\n<p><strong><span style=\"color: #283583;\">Lyon, France, 13 juillet 2023, 18h00 CET &#8211; <\/span><\/strong><a href=\"https:\/\/www.maatpharma.com\/fr\/\"><strong>MaaT\u00a0Pharma<\/strong><\/a> <strong><span style=\"color: #283583;\">(EURONEXT : MAAT &#8211; la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 de biotechnologies en stade clinique avanc\u00e9, leader dans le d\u00e9veloppement de Microbiome Ecosystem Therapies<sup>TM<\/sup> (MET)<sup>1<\/sup> visant \u00e0 am\u00e9liorer la survie des patients atteints de cancers, <\/span><\/strong>annonce aujourd\u2019hui le bilan semestriel de son contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de Bourse Kepler Cheuvreux.<\/p>\n<p>Au titre du contrat de liquidit\u00e9 confi\u00e9 par la soci\u00e9t\u00e9 Maat Pharma \u00e0 Kepler Cheuvreux, \u00e0 la date du 30 juin 2023, les moyens suivants figuraient au compte de liquidit\u00e9 :<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>15 484 titres<\/li>\n<li>41 13 \u20ac en esp\u00e8ces<\/li>\n<li>Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 552<\/li>\n<li>Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 431<\/li>\n<li>Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 15 974 titres pour 144 75 \u20ac<\/li>\n<li>Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 12 997 titres pour 122 16 \u20ac<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Il est rappel\u00e9 :<\/p>\n<ul>\n<li>que lors du dernier bilan du 31 d\u00e9cembre 2022, les moyens suivants figuraient au compte de liquidit\u00e9\u00a0:\n<ul>\n<li>12 507 titres<\/li>\n<li>63 045.61 \u20ac en esp\u00e8ces<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 390<\/li>\n<li>Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 330<\/li>\n<li>Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 14 188 titres pour 131 237.39 \u20ac<\/li>\n<li>Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 9 342 titres pour 86 141.84 \u20ac<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li>que lors de la mise en place du contrat, les moyens suivants figuraient au compte de liquidit\u00e9 :\n<ul>\n<li>0 titres<\/li>\n<li>200 000.00 \u20ac en esp\u00e8ces<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>La mise en \u0153uvre du pr\u00e9sent bilan est r\u00e9alis\u00e9e conform\u00e9ment \u00e0 la d\u00e9cision AMF n\u00b02021-01 du 22 juin 2021 renouvelant l\u2019instauration des contrats de liquidit\u00e9 sur titres de capital au titre de pratique de march\u00e9 admise.<\/p>\n<p>&nbsp;<\/p>\n<table width=\"607\">\n<tbody>\n<tr>\n<td width=\"74\"><\/td>\n<td colspan=\"3\" width=\"261\">Achats<\/td>\n<td width=\"11\"><\/td>\n<td colspan=\"3\" width=\"261\">Ventes<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td width=\"74\">Nombre de<br \/>\ntransactions<\/td>\n<td width=\"74\">Nombre de<br \/>\ntitres<\/td>\n<td width=\"113\">Capitaux en EUR<\/td>\n<td><\/td>\n<td width=\"74\">Nombre de<br \/>\ntransactions<\/td>\n<td width=\"74\">Nombre de<br \/>\ntitres<\/td>\n<td width=\"113\">Capitaux en EUR<\/td>\n<\/tr>\n<tr>\n<td>Total<\/td>\n<td>552<\/td>\n<td>15\u00a0974<\/td>\n<td>144\u00a0745.75<\/td>\n<td><\/td>\n<td>431<\/td>\n<td>12\u00a0997<\/td>\n<td>122\u00a0384.16<\/td>\n<\/tr>\n<tr>\n<td>02\/01\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>8.02<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>67<\/td>\n<td>539.35<\/td>\n<\/tr>\n<tr>\n<td>03\/01\/2023<\/td>\n<td>1<\/td>\n<td>5<\/td>\n<td>40.00<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>20<\/td>\n<td>161.60<\/td>\n<\/tr>\n<tr>\n<td>04\/01\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>14<\/td>\n<td>460<\/td>\n<td>3\u00a0910.00<\/td>\n<\/tr>\n<tr>\n<td>05\/01\/2023<\/td>\n<td>9<\/td>\n<td>281<\/td>\n<td>2\u00a0554.29<\/td>\n<td><\/td>\n<td>14<\/td>\n<td>493<\/td>\n<td>4\u00a0757.45<\/td>\n<\/tr>\n<tr>\n<td>06\/01\/2023<\/td>\n<td>4<\/td>\n<td>88<\/td>\n<td>796.40<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>09\/01\/2023<\/td>\n<td>5<\/td>\n<td>261<\/td>\n<td>2\u00a0268.09<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>10\/01\/2023<\/td>\n<td>2<\/td>\n<td>41<\/td>\n<td>348.50<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>8.62<\/td>\n<\/tr>\n<tr>\n<td>11\/01\/2023<\/td>\n<td>6<\/td>\n<td>139<\/td>\n<td>1\u00a0167.60<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>49<\/td>\n<td>416.50<\/td>\n<\/tr>\n<tr>\n<td>12\/01\/2023<\/td>\n<td>8<\/td>\n<td>222<\/td>\n<td>1\u00a0847.04<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>13\/01\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>8<\/td>\n<td>220<\/td>\n<td>1\u00a0867.80<\/td>\n<\/tr>\n<tr>\n<td>16\/01\/2023<\/td>\n<td>8<\/td>\n<td>200<\/td>\n<td>1\u00a0726.00<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>150<\/td>\n<td>1\u00a0326.00<\/td>\n<\/tr>\n<tr>\n<td>17\/01\/2023<\/td>\n<td>2<\/td>\n<td>60<\/td>\n<td>519.00<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>41<\/td>\n<td>360.80<\/td>\n<\/tr>\n<tr>\n<td>18\/01\/2023<\/td>\n<td>2<\/td>\n<td>70<\/td>\n<td>602.00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>40<\/td>\n<td>348.00<\/td>\n<\/tr>\n<tr>\n<td>19\/01\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>59<\/td>\n<td>522.15<\/td>\n<\/tr>\n<tr>\n<td>20\/01\/2023<\/td>\n<td>4<\/td>\n<td>130<\/td>\n<td>1\u00a0140.10<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>250<\/td>\n<td>2\u00a0250.00<\/td>\n<\/tr>\n<tr>\n<td>23\/01\/2023<\/td>\n<td>2<\/td>\n<td>50<\/td>\n<td>424.00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>30<\/td>\n<td>258.00<\/td>\n<\/tr>\n<tr>\n<td>24\/01\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>8.62<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>62<\/td>\n<td>543.74<\/td>\n<\/tr>\n<tr>\n<td>25\/01\/2023<\/td>\n<td>5<\/td>\n<td>185<\/td>\n<td>1\u00a0650.20<\/td>\n<td><\/td>\n<td>15<\/td>\n<td>499<\/td>\n<td>4\u00a0525.93<\/td>\n<\/tr>\n<tr>\n<td>26\/01\/2023<\/td>\n<td>4<\/td>\n<td>71<\/td>\n<td>641.13<\/td>\n<td><\/td>\n<td>6<\/td>\n<td>201<\/td>\n<td>1\u00a0839.15<\/td>\n<\/tr>\n<tr>\n<td>27\/01\/2023<\/td>\n<td>3<\/td>\n<td>60<\/td>\n<td>546.00<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>63<\/td>\n<td>580.86<\/td>\n<\/tr>\n<tr>\n<td>30\/01\/2023<\/td>\n<td>1<\/td>\n<td>50<\/td>\n<td>460.00<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>67<\/td>\n<td>623.10<\/td>\n<\/tr>\n<tr>\n<td>31\/01\/2023<\/td>\n<td>2<\/td>\n<td>51<\/td>\n<td>464.10<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>51<\/td>\n<td>469.20<\/td>\n<\/tr>\n<tr>\n<td>01\/02\/2023<\/td>\n<td>3<\/td>\n<td>101<\/td>\n<td>924.15<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>51<\/td>\n<td>472.26<\/td>\n<\/tr>\n<tr>\n<td>02\/02\/2023<\/td>\n<td>4<\/td>\n<td>185<\/td>\n<td>1\u00a0652.05<\/td>\n<td><\/td>\n<td>7<\/td>\n<td>300<\/td>\n<td>2\u00a0703.00<\/td>\n<\/tr>\n<tr>\n<td>03\/02\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>21<\/td>\n<td>596<\/td>\n<td>5\u00a0673.92<\/td>\n<\/tr>\n<tr>\n<td>06\/02\/2023<\/td>\n<td>13<\/td>\n<td>502<\/td>\n<td>4\u00a0663.58<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>150<\/td>\n<td>1\u00a0440.00<\/td>\n<\/tr>\n<tr>\n<td>07\/02\/2023<\/td>\n<td>4<\/td>\n<td>174<\/td>\n<td>1\u00a0599.06<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>50<\/td>\n<td>467.00<\/td>\n<\/tr>\n<tr>\n<td>08\/02\/2023<\/td>\n<td>20<\/td>\n<td>654<\/td>\n<td>5\u00a0886.00<\/td>\n<td><\/td>\n<td>7<\/td>\n<td>300<\/td>\n<td>2\u00a0814.00<\/td>\n<\/tr>\n<tr>\n<td>09\/02\/2023<\/td>\n<td>8<\/td>\n<td>330<\/td>\n<td>2\u00a0880.90<\/td>\n<td><\/td>\n<td>6<\/td>\n<td>152<\/td>\n<td>1\u00a0377.12<\/td>\n<\/tr>\n<tr>\n<td>10\/02\/2023<\/td>\n<td>5<\/td>\n<td>202<\/td>\n<td>1\u00a0801.84<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>140<\/td>\n<td>1\u00a0261.40<\/td>\n<\/tr>\n<tr>\n<td>13\/02\/2023<\/td>\n<td>7<\/td>\n<td>353<\/td>\n<td>3\u00a0014.62<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>180<\/td>\n<td>1\u00a0562.40<\/td>\n<\/tr>\n<tr>\n<td>14\/02\/2023<\/td>\n<td>3<\/td>\n<td>110<\/td>\n<td>957.00<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>131<\/td>\n<td>1\u00a0151.49<\/td>\n<\/tr>\n<tr>\n<td>15\/02\/2023<\/td>\n<td>4<\/td>\n<td>112<\/td>\n<td>976.64<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>80<\/td>\n<td>707.20<\/td>\n<\/tr>\n<tr>\n<td>16\/02\/2023<\/td>\n<td>3<\/td>\n<td>90<\/td>\n<td>812.70<\/td>\n<td><\/td>\n<td>9<\/td>\n<td>311<\/td>\n<td>2\u00a0839.43<\/td>\n<\/tr>\n<tr>\n<td>17\/02\/2023<\/td>\n<td>5<\/td>\n<td>61<\/td>\n<td>559.98<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>50<\/td>\n<td>460.00<\/td>\n<\/tr>\n<tr>\n<td>20\/02\/2023<\/td>\n<td>3<\/td>\n<td>98<\/td>\n<td>909.44<\/td>\n<td><\/td>\n<td>6<\/td>\n<td>199<\/td>\n<td>1\u00a0864.63<\/td>\n<\/tr>\n<tr>\n<td>21\/02\/2023<\/td>\n<td>3<\/td>\n<td>73<\/td>\n<td>675.98<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>51<\/td>\n<td>474.30<\/td>\n<\/tr>\n<tr>\n<td>22\/02\/2023<\/td>\n<td>4<\/td>\n<td>63<\/td>\n<td>598.50<\/td>\n<td><\/td>\n<td>16<\/td>\n<td>689<\/td>\n<td>6\u00a0724.64<\/td>\n<\/tr>\n<tr>\n<td>23\/02\/2023<\/td>\n<td>7<\/td>\n<td>144<\/td>\n<td>1\u00a0368.00<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>155<\/td>\n<td>1\u00a0488.00<\/td>\n<\/tr>\n<tr>\n<td>24\/02\/2023<\/td>\n<td>7<\/td>\n<td>215<\/td>\n<td>2\u00a0126.35<\/td>\n<td><\/td>\n<td>13<\/td>\n<td>510<\/td>\n<td>5\u00a0120.40<\/td>\n<\/tr>\n<tr>\n<td>27\/02\/2023<\/td>\n<td>4<\/td>\n<td>100<\/td>\n<td>1\u00a0005.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>28\/02\/2023<\/td>\n<td>3<\/td>\n<td>105<\/td>\n<td>1\u00a0033.20<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>106<\/td>\n<td>1\u00a0061.06<\/td>\n<\/tr>\n<tr>\n<td>01\/03\/2023<\/td>\n<td>4<\/td>\n<td>120<\/td>\n<td>1\u00a0207.20<\/td>\n<td><\/td>\n<td>16<\/td>\n<td>1\u00a0071<\/td>\n<td>11\u00a0288.34<\/td>\n<\/tr>\n<tr>\n<td>02\/03\/2023<\/td>\n<td>6<\/td>\n<td>105<\/td>\n<td>1\u00a0121.40<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>03\/03\/2023<\/td>\n<td>16<\/td>\n<td>450<\/td>\n<td>4\u00a0846.50<\/td>\n<td><\/td>\n<td>8<\/td>\n<td>350<\/td>\n<td>3\u00a0853.50<\/td>\n<\/tr>\n<tr>\n<td>06\/03\/2023<\/td>\n<td>5<\/td>\n<td>184<\/td>\n<td>1\u00a0928.32<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>148<\/td>\n<td>1\u00a0567.32<\/td>\n<\/tr>\n<tr>\n<td>07\/03\/2023<\/td>\n<td>5<\/td>\n<td>76<\/td>\n<td>801.04<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>121<\/td>\n<td>1\u00a0291.07<\/td>\n<\/tr>\n<tr>\n<td>08\/03\/2023<\/td>\n<td>4<\/td>\n<td>94<\/td>\n<td>1\u00a0000.16<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>41<\/td>\n<td>442.80<\/td>\n<\/tr>\n<tr>\n<td>09\/03\/2023<\/td>\n<td>17<\/td>\n<td>583<\/td>\n<td>5\u00a0853.32<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>30<\/td>\n<td>303.00<\/td>\n<\/tr>\n<tr>\n<td>10\/03\/2023<\/td>\n<td>3<\/td>\n<td>60<\/td>\n<td>595.80<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>13\/03\/2023<\/td>\n<td>20<\/td>\n<td>730<\/td>\n<td>6\u00a0942.30<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>60<\/td>\n<td>576.00<\/td>\n<\/tr>\n<tr>\n<td>14\/03\/2023<\/td>\n<td>6<\/td>\n<td>80<\/td>\n<td>765.60<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>160<\/td>\n<td>1\u00a0556.80<\/td>\n<\/tr>\n<tr>\n<td>15\/03\/2023<\/td>\n<td>6<\/td>\n<td>151<\/td>\n<td>1\u00a0449.60<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>9.72<\/td>\n<\/tr>\n<tr>\n<td>16\/03\/2023<\/td>\n<td>3<\/td>\n<td>51<\/td>\n<td>484.50<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>41<\/td>\n<td>393.60<\/td>\n<\/tr>\n<tr>\n<td>17\/03\/2023<\/td>\n<td>5<\/td>\n<td>150<\/td>\n<td>1\u00a0438.50<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>64<\/td>\n<td>627.20<\/td>\n<\/tr>\n<tr>\n<td>20\/03\/2023<\/td>\n<td>1<\/td>\n<td>40<\/td>\n<td>376.00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>40<\/td>\n<td>380.00<\/td>\n<\/tr>\n<tr>\n<td>21\/03\/2023<\/td>\n<td>4<\/td>\n<td>41<\/td>\n<td>389.50<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>9.58<\/td>\n<\/tr>\n<tr>\n<td>22\/03\/2023<\/td>\n<td>1<\/td>\n<td>26<\/td>\n<td>247.00<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>146<\/td>\n<td>1\u00a0416.20<\/td>\n<\/tr>\n<tr>\n<td>23\/03\/2023<\/td>\n<td>2<\/td>\n<td>50<\/td>\n<td>489.00<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>39<\/td>\n<td>384.93<\/td>\n<\/tr>\n<tr>\n<td>24\/03\/2023<\/td>\n<td>20<\/td>\n<td>495<\/td>\n<td>4\u00a0653.00<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>77<\/td>\n<td>730.73<\/td>\n<\/tr>\n<tr>\n<td>27\/03\/2023<\/td>\n<td>14<\/td>\n<td>306<\/td>\n<td>2\u00a0836.62<\/td>\n<td><\/td>\n<td>12<\/td>\n<td>369<\/td>\n<td>3\u00a0516.57<\/td>\n<\/tr>\n<tr>\n<td>28\/03\/2023<\/td>\n<td>3<\/td>\n<td>95<\/td>\n<td>949.05<\/td>\n<td><\/td>\n<td>13<\/td>\n<td>365<\/td>\n<td>3\u00a0719.35<\/td>\n<\/tr>\n<tr>\n<td>29\/03\/2023<\/td>\n<td>12<\/td>\n<td>330<\/td>\n<td>3\u00a0313.20<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>60<\/td>\n<td>621.00<\/td>\n<\/tr>\n<tr>\n<td>30\/03\/2023<\/td>\n<td>3<\/td>\n<td>36<\/td>\n<td>355.32<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>70<\/td>\n<td>697.20<\/td>\n<\/tr>\n<tr>\n<td>31\/03\/2023<\/td>\n<td>2<\/td>\n<td>51<\/td>\n<td>510.00<\/td>\n<td><\/td>\n<td>6<\/td>\n<td>200<\/td>\n<td>2\u00a0054.00<\/td>\n<\/tr>\n<tr>\n<td>03\/04\/2023<\/td>\n<td>1<\/td>\n<td>18<\/td>\n<td>180.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>04\/04\/2023<\/td>\n<td>5<\/td>\n<td>83<\/td>\n<td>830.00<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>6<\/td>\n<td>60.54<\/td>\n<\/tr>\n<tr>\n<td>05\/04\/2023<\/td>\n<td>2<\/td>\n<td>70<\/td>\n<td>700.00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>12<\/td>\n<td>121.20<\/td>\n<\/tr>\n<tr>\n<td>06\/04\/2023<\/td>\n<td>2<\/td>\n<td>51<\/td>\n<td>510.00<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>11<\/td>\n<td>111.10<\/td>\n<\/tr>\n<tr>\n<td>11\/04\/2023<\/td>\n<td>5<\/td>\n<td>50<\/td>\n<td>500.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>12\/04\/2023<\/td>\n<td>9<\/td>\n<td>158<\/td>\n<td>1\u00a0537.34<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>90<\/td>\n<td>887.40<\/td>\n<\/tr>\n<tr>\n<td>13\/04\/2023<\/td>\n<td>7<\/td>\n<td>90<\/td>\n<td>894.60<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>14\/04\/2023<\/td>\n<td>7<\/td>\n<td>210<\/td>\n<td>2\u00a0037.00<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>50<\/td>\n<td>490.00<\/td>\n<\/tr>\n<tr>\n<td>17\/04\/2023<\/td>\n<td>13<\/td>\n<td>375<\/td>\n<td>3\u00a0562.50<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>65<\/td>\n<td>624.00<\/td>\n<\/tr>\n<tr>\n<td>18\/04\/2023<\/td>\n<td>3<\/td>\n<td>120<\/td>\n<td>1\u00a0138.80<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>32<\/td>\n<td>304.32<\/td>\n<\/tr>\n<tr>\n<td>19\/04\/2023<\/td>\n<td>2<\/td>\n<td>80<\/td>\n<td>752.00<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>49<\/td>\n<td>465.50<\/td>\n<\/tr>\n<tr>\n<td>21\/04\/2023<\/td>\n<td>2<\/td>\n<td>20<\/td>\n<td>190.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>24\/04\/2023<\/td>\n<td>6<\/td>\n<td>243<\/td>\n<td>2\u00a0340.09<\/td>\n<td><\/td>\n<td>10<\/td>\n<td>339<\/td>\n<td>3\u00a0328.98<\/td>\n<\/tr>\n<tr>\n<td>25\/04\/2023<\/td>\n<td>3<\/td>\n<td>100<\/td>\n<td>977.00<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>160<\/td>\n<td>1\u00a0580.80<\/td>\n<\/tr>\n<tr>\n<td>26\/04\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>9.72<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>9.72<\/td>\n<\/tr>\n<tr>\n<td>27\/04\/2023<\/td>\n<td>4<\/td>\n<td>110<\/td>\n<td>1\u00a0052.70<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>28\/04\/2023<\/td>\n<td>16<\/td>\n<td>528<\/td>\n<td>4\u00a0778.40<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>170<\/td>\n<td>1\u00a0558.90<\/td>\n<\/tr>\n<tr>\n<td>02\/05\/2023<\/td>\n<td>3<\/td>\n<td>50<\/td>\n<td>454.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>03\/05\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>9.08<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>9.08<\/td>\n<\/tr>\n<tr>\n<td>04\/05\/2023<\/td>\n<td>9<\/td>\n<td>230<\/td>\n<td>2\u00a0017.10<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>19<\/td>\n<td>167.39<\/td>\n<\/tr>\n<tr>\n<td>05\/05\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>7<\/td>\n<td>92<\/td>\n<td>821.56<\/td>\n<\/tr>\n<tr>\n<td>08\/05\/2023<\/td>\n<td>7<\/td>\n<td>146<\/td>\n<td>1\u00a0278.96<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>8.92<\/td>\n<\/tr>\n<tr>\n<td>09\/05\/2023<\/td>\n<td>3<\/td>\n<td>60<\/td>\n<td>522.00<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>50<\/td>\n<td>440.00<\/td>\n<\/tr>\n<tr>\n<td>10\/05\/2023<\/td>\n<td>6<\/td>\n<td>214<\/td>\n<td>1\u00a0821.14<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>50<\/td>\n<td>440.00<\/td>\n<\/tr>\n<tr>\n<td>11\/05\/2023<\/td>\n<td>8<\/td>\n<td>156<\/td>\n<td>1\u00a0285.44<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>87<\/td>\n<td>727.32<\/td>\n<\/tr>\n<tr>\n<td>12\/05\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>8.28<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>84<\/td>\n<td>709.80<\/td>\n<\/tr>\n<tr>\n<td>15\/05\/2023<\/td>\n<td>4<\/td>\n<td>131<\/td>\n<td>1\u00a0074.20<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>170<\/td>\n<td>1\u00a0434.80<\/td>\n<\/tr>\n<tr>\n<td>16\/05\/2023<\/td>\n<td>3<\/td>\n<td>110<\/td>\n<td>936.10<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>100<\/td>\n<td>865.00<\/td>\n<\/tr>\n<tr>\n<td>17\/05\/2023<\/td>\n<td>1<\/td>\n<td>40<\/td>\n<td>332.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>19\/05\/2023<\/td>\n<td>6<\/td>\n<td>354<\/td>\n<td>2\u00a0842.62<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>22\/05\/2023<\/td>\n<td>1<\/td>\n<td>50<\/td>\n<td>400.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>23\/05\/2023<\/td>\n<td>5<\/td>\n<td>40<\/td>\n<td>320.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>24\/05\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>7.98<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>41<\/td>\n<td>328.00<\/td>\n<\/tr>\n<tr>\n<td>25\/05\/2023<\/td>\n<td>3<\/td>\n<td>50<\/td>\n<td>400.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>29\/05\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>101<\/td>\n<td>828.20<\/td>\n<\/tr>\n<tr>\n<td>30\/05\/2023<\/td>\n<td>2<\/td>\n<td>31<\/td>\n<td>251.10<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>8.20<\/td>\n<\/tr>\n<tr>\n<td>31\/05\/2023<\/td>\n<td>1<\/td>\n<td>50<\/td>\n<td>400.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>01\/06\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>7.98<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>7.98<\/td>\n<\/tr>\n<tr>\n<td>05\/06\/2023<\/td>\n<td>2<\/td>\n<td>30<\/td>\n<td>240.00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>30<\/td>\n<td>243.00<\/td>\n<\/tr>\n<tr>\n<td>06\/06\/2023<\/td>\n<td>3<\/td>\n<td>170<\/td>\n<td>1\u00a0353.20<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>8.20<\/td>\n<\/tr>\n<tr>\n<td>07\/06\/2023<\/td>\n<td>3<\/td>\n<td>151<\/td>\n<td>1\u00a0182.33<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>7.90<\/td>\n<\/tr>\n<tr>\n<td>08\/06\/2023<\/td>\n<td>3<\/td>\n<td>91<\/td>\n<td>715.26<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>7.90<\/td>\n<\/tr>\n<tr>\n<td>09\/06\/2023<\/td>\n<td>4<\/td>\n<td>91<\/td>\n<td>707.07<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>51<\/td>\n<td>402.90<\/td>\n<\/tr>\n<tr>\n<td>12\/06\/2023<\/td>\n<td>6<\/td>\n<td>256<\/td>\n<td>1\u00a0966.08<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>64<\/td>\n<td>493.44<\/td>\n<\/tr>\n<tr>\n<td>13\/06\/2023<\/td>\n<td>2<\/td>\n<td>80<\/td>\n<td>616.00<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>112<\/td>\n<td>873.60<\/td>\n<\/tr>\n<tr>\n<td>14\/06\/2023<\/td>\n<td>4<\/td>\n<td>116<\/td>\n<td>886.24<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>67<\/td>\n<td>513.22<\/td>\n<\/tr>\n<tr>\n<td>15\/06\/2023<\/td>\n<td>3<\/td>\n<td>140<\/td>\n<td>1\u00a0045.80<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>27<\/td>\n<td>202.50<\/td>\n<\/tr>\n<tr>\n<td>16\/06\/2023<\/td>\n<td>1<\/td>\n<td>3<\/td>\n<td>22.50<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>80<\/td>\n<td>608.00<\/td>\n<\/tr>\n<tr>\n<td>19\/06\/2023<\/td>\n<td>8<\/td>\n<td>282<\/td>\n<td>2\u00a0092.44<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>160<\/td>\n<td>1\u00a0214.40<\/td>\n<\/tr>\n<tr>\n<td>21\/06\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>60<\/td>\n<td>448.20<\/td>\n<\/tr>\n<tr>\n<td>22\/06\/2023<\/td>\n<td>2<\/td>\n<td>70<\/td>\n<td>520.80<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>23\/06\/2023<\/td>\n<td>4<\/td>\n<td>101<\/td>\n<td>737.30<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>61<\/td>\n<td>457.50<\/td>\n<\/tr>\n<tr>\n<td>26\/06\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>7.28<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>7.28<\/td>\n<\/tr>\n<tr>\n<td>27\/06\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>20<\/td>\n<td>148.00<\/td>\n<\/tr>\n<tr>\n<td>28\/06\/2023<\/td>\n<td>5<\/td>\n<td>194<\/td>\n<td>1\u00a0402.62<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>29\/06\/2023<\/td>\n<td>4<\/td>\n<td>203<\/td>\n<td>1\u00a0467.69<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>30\/06\/2023<\/td>\n<td>1<\/td>\n<td>30<\/td>\n<td>216.00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"color: #283583;\"><strong>A propos de MaaT Pharma<\/strong><\/span><\/p>\n<p>MaaT Pharma est une soci\u00e9t\u00e9 de biotechnologies au stade clinique qui a mis au point une approche compl\u00e8te pour restaurer la symbiose microbiote\/h\u00f4te des patients atteints de cancers. Engag\u00e9e dans le traitement des cancers et de la maladie du greffon contre l\u2019h\u00f4te (GvH), une complication grave survenant apr\u00e8s une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques, MaaT Pharma a lanc\u00e9 en mars 2022 en Europe un essai clinique de Phase 3 chez des patients atteints de GvH aigu\u00eb, apr\u00e8s avoir r\u00e9alis\u00e9 la preuve de concept de son approche dans un essai clinique de Phase 2. Sa puissante plateforme de d\u00e9couverte et d\u2019analyse, gutPrint\u00ae soutient le d\u00e9veloppement de son portefeuille de produits et son extension \u00e0 des indications plus larges, en aidant \u00e0 d\u00e9terminer de nouvelles cibles th\u00e9rapeutiques, \u00e0 \u00e9valuer les m\u00e9dicaments candidats et \u00e0 identifier des biomarqueurs pour la prise en charge de pathologies impliquant le microbiote. Les <em>Microbiome Ecosystem Therapies<sup>TM <\/sup><\/em>(Microbioth\u00e9rapies \u00e0 \u00e9cosyst\u00e8me complet) sont toutes produites dans le cadre tr\u00e8s standardis\u00e9 d\u2019une fabrication et de contr\u00f4les qualit\u00e9 cGMP, afin de garantir en toute s\u00e9curit\u00e9 l\u2019acc\u00e8s \u00e0 la diversit\u00e9 et \u00e0 la richesse du microbiote, sous forme orale ou d\u2019<em>enema<\/em>. MaaT Pharma b\u00e9n\u00e9ficie de l\u2019engagement de scientifiques de renomm\u00e9e mondiale et de relations \u00e9tablies avec les instances r\u00e9glementaires pour faire progresser l\u2019int\u00e9gration des th\u00e9rapies \u00e0 base de microbiote dans la pratique clinique.<\/p>\n<p>MaaT Pharma est la premi\u00e8re soci\u00e9t\u00e9 d\u00e9veloppant des m\u00e9dicaments \u00e0 base de microbiote cot\u00e9e sur Euronext Paris (Code mn\u00e9monique : MAAT).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux\u00a0 Lyon, France, 13 juillet 2023, 18h00 CET &#8211; MaaT\u00a0Pharma (EURONEXT : MAAT &#8211; la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 de biotechnologies en stade clinique avanc\u00e9, leader dans le d\u00e9veloppement de Microbiome Ecosystem TherapiesTM (MET)1 visant \u00e0 am\u00e9liorer la survie des patients atteints de cancers, annonce aujourd\u2019hui le bilan semestriel de son contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de Bourse Kepler Cheuvreux. Au titre du contrat de liquidit\u00e9 confi\u00e9 par la soci\u00e9t\u00e9 Maat Pharma \u00e0 Kepler Cheuvreux, \u00e0 la date du 30 juin 2023, les moyens suivants figuraient au compte de liquidit\u00e9 : 15 484 titres 41 13 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 552 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 431 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 15 974 titres pour 144 75 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 12 997 titres pour 122 16 \u20ac Il est rappel\u00e9 : que lors du dernier bilan du 31 d\u00e9cembre 2022, les moyens suivants figuraient au compte de liquidit\u00e9\u00a0: 12 507 titres 63 045.61 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 390 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 330 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 14 188 titres pour 131 237.39 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 9 342 titres pour 86 141.84 \u20ac que lors de la mise en place du contrat, les moyens suivants figuraient au compte de liquidit\u00e9 : 0 titres 200 000.00 \u20ac en esp\u00e8ces La mise en \u0153uvre du pr\u00e9sent bilan est r\u00e9alis\u00e9e conform\u00e9ment \u00e0 la d\u00e9cision AMF n\u00b02021-01 du 22 juin 2021 renouvelant l\u2019instauration des contrats de liquidit\u00e9 sur titres de capital au titre de pratique de march\u00e9 admise. &nbsp; Achats Ventes Nombre de transactions Nombre de titres Capitaux en EUR Nombre de transactions Nombre de titres Capitaux en EUR Total 552 15\u00a0974 144\u00a0745.75 431 12\u00a0997 122\u00a0384.16 02\/01\/2023 1 1 8.02 4 67 539.35 03\/01\/2023 1 5 40.00 2 20 161.60 04\/01\/2023 &#8211; &#8211; &#8211; 14 460 3\u00a0910.00 05\/01\/2023 9 281 2\u00a0554.29 14 493 4\u00a0757.45 06\/01\/2023 4 88 796.40 &#8211; &#8211; &#8211; 09\/01\/2023 5 261 2\u00a0268.09 &#8211; &#8211; &#8211; 10\/01\/2023 2 41 348.50 1 1 8.62 11\/01\/2023 6 139 1\u00a0167.60 2 49 416.50 12\/01\/2023 8 222 1\u00a0847.04 &#8211; &#8211; &#8211; 13\/01\/2023 &#8211; &#8211; &#8211; 8 220 1\u00a0867.80 16\/01\/2023 8 200 1\u00a0726.00 5 150 1\u00a0326.00 17\/01\/2023 2 60 519.00 2 41 360.80 18\/01\/2023 2 70 602.00 1 40 348.00 19\/01\/2023 &#8211; &#8211; &#8211; 4 59 522.15 20\/01\/2023 4 130 1\u00a0140.10 4 250 2\u00a0250.00 23\/01\/2023 2 50 424.00 1 30 258.00 24\/01\/2023 1 1 8.62 4 62 543.74 25\/01\/2023 5 185 1\u00a0650.20 15 499 4\u00a0525.93 26\/01\/2023 4 71 641.13 6 201 1\u00a0839.15 27\/01\/2023 3 60 546.00 2 63 580.86 30\/01\/2023 1 50 460.00 5 67 623.10 31\/01\/2023 2 51 464.10 2 51 469.20 01\/02\/2023 3 101 924.15 4 51 472.26 02\/02\/2023 4 185 1\u00a0652.05 7 300 2\u00a0703.00 03\/02\/2023 &#8211; &#8211; &#8211; 21 596 5\u00a0673.92 06\/02\/2023 13 502 4\u00a0663.58 4 150 1\u00a0440.00 07\/02\/2023 4 174 1\u00a0599.06 1 50 467.00 08\/02\/2023 20 654 5\u00a0886.00 7 300 2\u00a0814.00 09\/02\/2023 8 330 2\u00a0880.90 6 152 1\u00a0377.12 10\/02\/2023 5 202 1\u00a0801.84 4 140 1\u00a0261.40 13\/02\/2023 7 353 3\u00a0014.62 5 180 1\u00a0562.40 14\/02\/2023 3 110 957.00 5 131 1\u00a0151.49 15\/02\/2023 4 112 976.64 3 80 707.20 16\/02\/2023 3 90 812.70 9 311 2\u00a0839.43 17\/02\/2023 5 61 559.98 1 50 460.00 20\/02\/2023 3 98 909.44 6 199 1\u00a0864.63 21\/02\/2023 3 73 675.98 3 51 474.30 22\/02\/2023 4 63 598.50 16 689 6\u00a0724.64 23\/02\/2023 7 144 1\u00a0368.00 5 155 1\u00a0488.00 24\/02\/2023 7 215 2\u00a0126.35 13 510 5\u00a0120.40 27\/02\/2023 4 100 1\u00a0005.00 &#8211; &#8211; &#8211; 28\/02\/2023 3 105 1\u00a0033.20 2 106 1\u00a0061.06 01\/03\/2023 4 120 1\u00a0207.20 16 1\u00a0071 11\u00a0288.34 02\/03\/2023 6 105 1\u00a0121.40 &#8211; &#8211; &#8211; 03\/03\/2023 16 450 4\u00a0846.50 8 350 3\u00a0853.50 06\/03\/2023 5 184 1\u00a0928.32 4 148 1\u00a0567.32 07\/03\/2023 5 76 801.04 4 121 1\u00a0291.07 08\/03\/2023 4 94 1\u00a0000.16 3 41 442.80 09\/03\/2023 17 583 5\u00a0853.32 3 30 303.00 10\/03\/2023 3 60 595.80 &#8211; &#8211; &#8211; 13\/03\/2023 20 730 6\u00a0942.30 1 60 576.00 14\/03\/2023 6 80 765.60 5 160 1\u00a0556.80 15\/03\/2023 6 151 1\u00a0449.60 1 1 9.72 16\/03\/2023 3 51 484.50 3 41 393.60 17\/03\/2023 5 150 1\u00a0438.50 3 64 627.20 20\/03\/2023 1 40 376.00 1 40 380.00 21\/03\/2023 4 41 389.50 1 1 9.58 22\/03\/2023 1 26 247.00 4 146 1\u00a0416.20 23\/03\/2023 2 50 489.00 2 39 384.93 24\/03\/2023 20 495 4\u00a0653.00 4 77 730.73 27\/03\/2023 14 306 2\u00a0836.62 12 369 3\u00a0516.57 28\/03\/2023 3 95 949.05 13 365 3\u00a0719.35 29\/03\/2023 12 330 3\u00a0313.20 3 60 621.00 30\/03\/2023 3 36 355.32 3 70 697.20 31\/03\/2023 2 51 510.00 6 200 2\u00a0054.00 03\/04\/2023 1 18 180.00 &#8211; &#8211; &#8211; 04\/04\/2023 5 83 830.00 2 6 60.54 05\/04\/2023 2 70 700.00 1 12 121.20 06\/04\/2023 2 51 510.00 3 11 111.10 11\/04\/2023 5 50 500.00 &#8211; &#8211; &#8211; 12\/04\/2023 9 158 1\u00a0537.34 3 90 887.40 13\/04\/2023 7 90 894.60 &#8211; &#8211; &#8211; 14\/04\/2023 7 210 2\u00a0037.00 2 50 490.00 17\/04\/2023 13 375 3\u00a0562.50 2 65 624.00 18\/04\/2023 3 120 1\u00a0138.80 3 32 304.32 19\/04\/2023 2 80 752.00 3 49 465.50 21\/04\/2023 2 20 190.00 &#8211; &#8211; &#8211; 24\/04\/2023 6 243 2\u00a0340.09 10 339 3\u00a0328.98 25\/04\/2023 3 100 977.00 4 160 1\u00a0580.80 26\/04\/2023 1 1 9.72 1 1 9.72 27\/04\/2023 4 110 1\u00a0052.70 &#8211; &#8211; &#8211; 28\/04\/2023 16 528 4\u00a0778.40 4 170 1\u00a0558.90 02\/05\/2023 3 50 454.00 &#8211; &#8211; &#8211; 03\/05\/2023 1 1 9.08 1 1 9.08 04\/05\/2023 9 230 2\u00a0017.10 4 19 167.39 05\/05\/2023 &#8211; &#8211; &#8211; 7 92 821.56 08\/05\/2023 7 146 1\u00a0278.96 1 1 8.92 09\/05\/2023 3 60 522.00 3 50 440.00 10\/05\/2023 6 214 1\u00a0821.14 2 50 440.00 11\/05\/2023 8 156 1\u00a0285.44 3 87 727.32 12\/05\/2023 1 1 8.28 4 84 709.80 15\/05\/2023 4 131 1\u00a0074.20 4 170 1\u00a0434.80 16\/05\/2023 3 110 936.10 4 100 865.00 17\/05\/2023 1 40 332.00 &#8211;<\/p>\n","protected":false},"author":2,"featured_media":7120,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[47],"class_list":["post-10418","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-fr","year_press-47"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux\u00a0 Lyon, France, 13 juillet 2023, 18h00 CET &#8211; MaaT\u00a0Pharma (EURONEXT : MAAT &#8211; la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 de biotechnologies en stade clinique avanc\u00e9, leader dans le d\u00e9veloppement de Microbiome Ecosystem TherapiesTM (MET)1 visant \u00e0 am\u00e9liorer la survie des patients atteints de cancers, annonce aujourd\u2019hui le bilan semestriel de son contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de Bourse Kepler Cheuvreux. Au titre du contrat de liquidit\u00e9 confi\u00e9 par la soci\u00e9t\u00e9 Maat Pharma \u00e0 Kepler Cheuvreux, \u00e0 la date du 30 juin 2023, les moyens suivants figuraient au compte de liquidit\u00e9 : 15 484 titres 41 13 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 552 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 431 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 15 974 titres pour 144 75 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 12 997 titres pour 122 16 \u20ac Il est rappel\u00e9 : que lors du dernier bilan du 31 d\u00e9cembre 2022, les moyens suivants figuraient au compte de liquidit\u00e9\u00a0: 12 507 titres 63 045.61 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 390 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 330 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 14 188 titres pour 131 237.39 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 9 342 titres pour 86 141.84 \u20ac que lors de la mise en place du contrat, les moyens suivants figuraient au compte de liquidit\u00e9 : 0 titres 200 000.00 \u20ac en esp\u00e8ces La mise en \u0153uvre du pr\u00e9sent bilan est r\u00e9alis\u00e9e conform\u00e9ment \u00e0 la d\u00e9cision AMF n\u00b02021-01 du 22 juin 2021 renouvelant l\u2019instauration des contrats de liquidit\u00e9 sur titres de capital au titre de pratique de march\u00e9 admise. &nbsp; Achats Ventes Nombre de transactions Nombre de titres Capitaux en EUR Nombre de transactions Nombre de titres Capitaux en EUR Total 552 15\u00a0974 144\u00a0745.75 431 12\u00a0997 122\u00a0384.16 02\/01\/2023 1 1 8.02 4 67 539.35 03\/01\/2023 1 5 40.00 2 20 161.60 04\/01\/2023 &#8211; &#8211; &#8211; 14 460 3\u00a0910.00 05\/01\/2023 9 281 2\u00a0554.29 14 493 4\u00a0757.45 06\/01\/2023 4 88 796.40 &#8211; &#8211; &#8211; 09\/01\/2023 5 261 2\u00a0268.09 &#8211; &#8211; &#8211; 10\/01\/2023 2 41 348.50 1 1 8.62 11\/01\/2023 6 139 1\u00a0167.60 2 49 416.50 12\/01\/2023 8 222 1\u00a0847.04 &#8211; &#8211; &#8211; 13\/01\/2023 &#8211; &#8211; &#8211; 8 220 1\u00a0867.80 16\/01\/2023 8 200 1\u00a0726.00 5 150 1\u00a0326.00 17\/01\/2023 2 60 519.00 2 41 360.80 18\/01\/2023 2 70 602.00 1 40 348.00 19\/01\/2023 &#8211; &#8211; &#8211; 4 59 522.15 20\/01\/2023 4 130 1\u00a0140.10 4 250 2\u00a0250.00 23\/01\/2023 2 50 424.00 1 30 258.00 24\/01\/2023 1 1 8.62 4 62 543.74 25\/01\/2023 5 185 1\u00a0650.20 15 499 4\u00a0525.93 26\/01\/2023 4 71 641.13 6 201 1\u00a0839.15 27\/01\/2023 3 60 546.00 2 63 580.86 30\/01\/2023 1 50 460.00 5 67 623.10 31\/01\/2023 2 51 464.10 2 51 469.20 01\/02\/2023 3 101 924.15 4 51 472.26 02\/02\/2023 4 185 1\u00a0652.05 7 300 2\u00a0703.00 03\/02\/2023 &#8211; &#8211; &#8211; 21 596 5\u00a0673.92 06\/02\/2023 13 502 4\u00a0663.58 4 150 1\u00a0440.00 07\/02\/2023 4 174 1\u00a0599.06 1 50 467.00 08\/02\/2023 20 654 5\u00a0886.00 7 300 2\u00a0814.00 09\/02\/2023 8 330 2\u00a0880.90 6 152 1\u00a0377.12 10\/02\/2023 5 202 1\u00a0801.84 4 140 1\u00a0261.40 13\/02\/2023 7 353 3\u00a0014.62 5 180 1\u00a0562.40 14\/02\/2023 3 110 957.00 5 131 1\u00a0151.49 15\/02\/2023 4 112 976.64 3 80 707.20 16\/02\/2023 3 90 812.70 9 311 2\u00a0839.43 17\/02\/2023 5 61 559.98 1 50 460.00 20\/02\/2023 3 98 909.44 6 199 1\u00a0864.63 21\/02\/2023 3 73 675.98 3 51 474.30 22\/02\/2023 4 63 598.50 16 689 6\u00a0724.64 23\/02\/2023 7 144 1\u00a0368.00 5 155 1\u00a0488.00 24\/02\/2023 7 215 2\u00a0126.35 13 510 5\u00a0120.40 27\/02\/2023 4 100 1\u00a0005.00 &#8211; &#8211; &#8211; 28\/02\/2023 3 105 1\u00a0033.20 2 106 1\u00a0061.06 01\/03\/2023 4 120 1\u00a0207.20 16 1\u00a0071 11\u00a0288.34 02\/03\/2023 6 105 1\u00a0121.40 &#8211; &#8211; &#8211; 03\/03\/2023 16 450 4\u00a0846.50 8 350 3\u00a0853.50 06\/03\/2023 5 184 1\u00a0928.32 4 148 1\u00a0567.32 07\/03\/2023 5 76 801.04 4 121 1\u00a0291.07 08\/03\/2023 4 94 1\u00a0000.16 3 41 442.80 09\/03\/2023 17 583 5\u00a0853.32 3 30 303.00 10\/03\/2023 3 60 595.80 &#8211; &#8211; &#8211; 13\/03\/2023 20 730 6\u00a0942.30 1 60 576.00 14\/03\/2023 6 80 765.60 5 160 1\u00a0556.80 15\/03\/2023 6 151 1\u00a0449.60 1 1 9.72 16\/03\/2023 3 51 484.50 3 41 393.60 17\/03\/2023 5 150 1\u00a0438.50 3 64 627.20 20\/03\/2023 1 40 376.00 1 40 380.00 21\/03\/2023 4 41 389.50 1 1 9.58 22\/03\/2023 1 26 247.00 4 146 1\u00a0416.20 23\/03\/2023 2 50 489.00 2 39 384.93 24\/03\/2023 20 495 4\u00a0653.00 4 77 730.73 27\/03\/2023 14 306 2\u00a0836.62 12 369 3\u00a0516.57 28\/03\/2023 3 95 949.05 13 365 3\u00a0719.35 29\/03\/2023 12 330 3\u00a0313.20 3 60 621.00 30\/03\/2023 3 36 355.32 3 70 697.20 31\/03\/2023 2 51 510.00 6 200 2\u00a0054.00 03\/04\/2023 1 18 180.00 &#8211; &#8211; &#8211; 04\/04\/2023 5 83 830.00 2 6 60.54 05\/04\/2023 2 70 700.00 1 12 121.20 06\/04\/2023 2 51 510.00 3 11 111.10 11\/04\/2023 5 50 500.00 &#8211; &#8211; &#8211; 12\/04\/2023 9 158 1\u00a0537.34 3 90 887.40 13\/04\/2023 7 90 894.60 &#8211; &#8211; &#8211; 14\/04\/2023 7 210 2\u00a0037.00 2 50 490.00 17\/04\/2023 13 375 3\u00a0562.50 2 65 624.00 18\/04\/2023 3 120 1\u00a0138.80 3 32 304.32 19\/04\/2023 2 80 752.00 3 49 465.50 21\/04\/2023 2 20 190.00 &#8211; &#8211; &#8211; 24\/04\/2023 6 243 2\u00a0340.09 10 339 3\u00a0328.98 25\/04\/2023 3 100 977.00 4 160 1\u00a0580.80 26\/04\/2023 1 1 9.72 1 1 9.72 27\/04\/2023 4 110 1\u00a0052.70 &#8211; &#8211; &#8211; 28\/04\/2023 16 528 4\u00a0778.40 4 170 1\u00a0558.90 02\/05\/2023 3 50 454.00 &#8211; &#8211; &#8211; 03\/05\/2023 1 1 9.08 1 1 9.08 04\/05\/2023 9 230 2\u00a0017.10 4 19 167.39 05\/05\/2023 &#8211; &#8211; &#8211; 7 92 821.56 08\/05\/2023 7 146 1\u00a0278.96 1 1 8.92 09\/05\/2023 3 60 522.00 3 50 440.00 10\/05\/2023 6 214 1\u00a0821.14 2 50 440.00 11\/05\/2023 8 156 1\u00a0285.44 3 87 727.32 12\/05\/2023 1 1 8.28 4 84 709.80 15\/05\/2023 4 131 1\u00a0074.20 4 170 1\u00a0434.80 16\/05\/2023 3 110 936.10 4 100 865.00 17\/05\/2023 1 40 332.00 &#8211;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-13T16:00:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T14:16:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2362\" \/>\n\t<meta property=\"og:image:height\" content=\"2362\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux\",\"datePublished\":\"2023-07-13T16:00:27+00:00\",\"dateModified\":\"2026-01-22T14:16:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\"},\"wordCount\":679,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/Website_maat_logo.png\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\",\"name\":\"13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/Website_maat_logo.png\",\"datePublished\":\"2023-07-13T16:00:27+00:00\",\"dateModified\":\"2026-01-22T14:16:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/Website_maat_logo.png\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/Website_maat_logo.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","og_locale":"fr_FR","og_type":"article","og_title":"13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma","og_description":"MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux\u00a0 Lyon, France, 13 juillet 2023, 18h00 CET &#8211; MaaT\u00a0Pharma (EURONEXT : MAAT &#8211; la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 de biotechnologies en stade clinique avanc\u00e9, leader dans le d\u00e9veloppement de Microbiome Ecosystem TherapiesTM (MET)1 visant \u00e0 am\u00e9liorer la survie des patients atteints de cancers, annonce aujourd\u2019hui le bilan semestriel de son contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de Bourse Kepler Cheuvreux. Au titre du contrat de liquidit\u00e9 confi\u00e9 par la soci\u00e9t\u00e9 Maat Pharma \u00e0 Kepler Cheuvreux, \u00e0 la date du 30 juin 2023, les moyens suivants figuraient au compte de liquidit\u00e9 : 15 484 titres 41 13 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 552 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 431 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 15 974 titres pour 144 75 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 12 997 titres pour 122 16 \u20ac Il est rappel\u00e9 : que lors du dernier bilan du 31 d\u00e9cembre 2022, les moyens suivants figuraient au compte de liquidit\u00e9\u00a0: 12 507 titres 63 045.61 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 390 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 330 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 14 188 titres pour 131 237.39 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 9 342 titres pour 86 141.84 \u20ac que lors de la mise en place du contrat, les moyens suivants figuraient au compte de liquidit\u00e9 : 0 titres 200 000.00 \u20ac en esp\u00e8ces La mise en \u0153uvre du pr\u00e9sent bilan est r\u00e9alis\u00e9e conform\u00e9ment \u00e0 la d\u00e9cision AMF n\u00b02021-01 du 22 juin 2021 renouvelant l\u2019instauration des contrats de liquidit\u00e9 sur titres de capital au titre de pratique de march\u00e9 admise. &nbsp; Achats Ventes Nombre de transactions Nombre de titres Capitaux en EUR Nombre de transactions Nombre de titres Capitaux en EUR Total 552 15\u00a0974 144\u00a0745.75 431 12\u00a0997 122\u00a0384.16 02\/01\/2023 1 1 8.02 4 67 539.35 03\/01\/2023 1 5 40.00 2 20 161.60 04\/01\/2023 &#8211; &#8211; &#8211; 14 460 3\u00a0910.00 05\/01\/2023 9 281 2\u00a0554.29 14 493 4\u00a0757.45 06\/01\/2023 4 88 796.40 &#8211; &#8211; &#8211; 09\/01\/2023 5 261 2\u00a0268.09 &#8211; &#8211; &#8211; 10\/01\/2023 2 41 348.50 1 1 8.62 11\/01\/2023 6 139 1\u00a0167.60 2 49 416.50 12\/01\/2023 8 222 1\u00a0847.04 &#8211; &#8211; &#8211; 13\/01\/2023 &#8211; &#8211; &#8211; 8 220 1\u00a0867.80 16\/01\/2023 8 200 1\u00a0726.00 5 150 1\u00a0326.00 17\/01\/2023 2 60 519.00 2 41 360.80 18\/01\/2023 2 70 602.00 1 40 348.00 19\/01\/2023 &#8211; &#8211; &#8211; 4 59 522.15 20\/01\/2023 4 130 1\u00a0140.10 4 250 2\u00a0250.00 23\/01\/2023 2 50 424.00 1 30 258.00 24\/01\/2023 1 1 8.62 4 62 543.74 25\/01\/2023 5 185 1\u00a0650.20 15 499 4\u00a0525.93 26\/01\/2023 4 71 641.13 6 201 1\u00a0839.15 27\/01\/2023 3 60 546.00 2 63 580.86 30\/01\/2023 1 50 460.00 5 67 623.10 31\/01\/2023 2 51 464.10 2 51 469.20 01\/02\/2023 3 101 924.15 4 51 472.26 02\/02\/2023 4 185 1\u00a0652.05 7 300 2\u00a0703.00 03\/02\/2023 &#8211; &#8211; &#8211; 21 596 5\u00a0673.92 06\/02\/2023 13 502 4\u00a0663.58 4 150 1\u00a0440.00 07\/02\/2023 4 174 1\u00a0599.06 1 50 467.00 08\/02\/2023 20 654 5\u00a0886.00 7 300 2\u00a0814.00 09\/02\/2023 8 330 2\u00a0880.90 6 152 1\u00a0377.12 10\/02\/2023 5 202 1\u00a0801.84 4 140 1\u00a0261.40 13\/02\/2023 7 353 3\u00a0014.62 5 180 1\u00a0562.40 14\/02\/2023 3 110 957.00 5 131 1\u00a0151.49 15\/02\/2023 4 112 976.64 3 80 707.20 16\/02\/2023 3 90 812.70 9 311 2\u00a0839.43 17\/02\/2023 5 61 559.98 1 50 460.00 20\/02\/2023 3 98 909.44 6 199 1\u00a0864.63 21\/02\/2023 3 73 675.98 3 51 474.30 22\/02\/2023 4 63 598.50 16 689 6\u00a0724.64 23\/02\/2023 7 144 1\u00a0368.00 5 155 1\u00a0488.00 24\/02\/2023 7 215 2\u00a0126.35 13 510 5\u00a0120.40 27\/02\/2023 4 100 1\u00a0005.00 &#8211; &#8211; &#8211; 28\/02\/2023 3 105 1\u00a0033.20 2 106 1\u00a0061.06 01\/03\/2023 4 120 1\u00a0207.20 16 1\u00a0071 11\u00a0288.34 02\/03\/2023 6 105 1\u00a0121.40 &#8211; &#8211; &#8211; 03\/03\/2023 16 450 4\u00a0846.50 8 350 3\u00a0853.50 06\/03\/2023 5 184 1\u00a0928.32 4 148 1\u00a0567.32 07\/03\/2023 5 76 801.04 4 121 1\u00a0291.07 08\/03\/2023 4 94 1\u00a0000.16 3 41 442.80 09\/03\/2023 17 583 5\u00a0853.32 3 30 303.00 10\/03\/2023 3 60 595.80 &#8211; &#8211; &#8211; 13\/03\/2023 20 730 6\u00a0942.30 1 60 576.00 14\/03\/2023 6 80 765.60 5 160 1\u00a0556.80 15\/03\/2023 6 151 1\u00a0449.60 1 1 9.72 16\/03\/2023 3 51 484.50 3 41 393.60 17\/03\/2023 5 150 1\u00a0438.50 3 64 627.20 20\/03\/2023 1 40 376.00 1 40 380.00 21\/03\/2023 4 41 389.50 1 1 9.58 22\/03\/2023 1 26 247.00 4 146 1\u00a0416.20 23\/03\/2023 2 50 489.00 2 39 384.93 24\/03\/2023 20 495 4\u00a0653.00 4 77 730.73 27\/03\/2023 14 306 2\u00a0836.62 12 369 3\u00a0516.57 28\/03\/2023 3 95 949.05 13 365 3\u00a0719.35 29\/03\/2023 12 330 3\u00a0313.20 3 60 621.00 30\/03\/2023 3 36 355.32 3 70 697.20 31\/03\/2023 2 51 510.00 6 200 2\u00a0054.00 03\/04\/2023 1 18 180.00 &#8211; &#8211; &#8211; 04\/04\/2023 5 83 830.00 2 6 60.54 05\/04\/2023 2 70 700.00 1 12 121.20 06\/04\/2023 2 51 510.00 3 11 111.10 11\/04\/2023 5 50 500.00 &#8211; &#8211; &#8211; 12\/04\/2023 9 158 1\u00a0537.34 3 90 887.40 13\/04\/2023 7 90 894.60 &#8211; &#8211; &#8211; 14\/04\/2023 7 210 2\u00a0037.00 2 50 490.00 17\/04\/2023 13 375 3\u00a0562.50 2 65 624.00 18\/04\/2023 3 120 1\u00a0138.80 3 32 304.32 19\/04\/2023 2 80 752.00 3 49 465.50 21\/04\/2023 2 20 190.00 &#8211; &#8211; &#8211; 24\/04\/2023 6 243 2\u00a0340.09 10 339 3\u00a0328.98 25\/04\/2023 3 100 977.00 4 160 1\u00a0580.80 26\/04\/2023 1 1 9.72 1 1 9.72 27\/04\/2023 4 110 1\u00a0052.70 &#8211; &#8211; &#8211; 28\/04\/2023 16 528 4\u00a0778.40 4 170 1\u00a0558.90 02\/05\/2023 3 50 454.00 &#8211; &#8211; &#8211; 03\/05\/2023 1 1 9.08 1 1 9.08 04\/05\/2023 9 230 2\u00a0017.10 4 19 167.39 05\/05\/2023 &#8211; &#8211; &#8211; 7 92 821.56 08\/05\/2023 7 146 1\u00a0278.96 1 1 8.92 09\/05\/2023 3 60 522.00 3 50 440.00 10\/05\/2023 6 214 1\u00a0821.14 2 50 440.00 11\/05\/2023 8 156 1\u00a0285.44 3 87 727.32 12\/05\/2023 1 1 8.28 4 84 709.80 15\/05\/2023 4 131 1\u00a0074.20 4 170 1\u00a0434.80 16\/05\/2023 3 110 936.10 4 100 865.00 17\/05\/2023 1 40 332.00 &#8211;","og_url":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","og_site_name":"MaaT Pharma","article_published_time":"2023-07-13T16:00:27+00:00","article_modified_time":"2026-01-22T14:16:46+00:00","og_image":[{"width":2362,"height":2362,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","type":"image\/png"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux","datePublished":"2023-07-13T16:00:27+00:00","dateModified":"2026-01-22T14:16:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/"},"wordCount":679,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","url":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","name":"13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","datePublished":"2023-07-13T16:00:27+00:00","dateModified":"2026-01-22T14:16:46+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/july-13-2023-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/fr\/"},{"@type":"ListItem","position":2,"name":"13 juillet 2023 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/10418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=10418"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/10418\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/7120"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=10418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=10418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=10418"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=10418"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=10418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}